Logo image of PEAR

PEAR THERAPEUTICS INC (PEAR) Stock Analyst Ratings

NASDAQ:PEAR - Nasdaq - US7047231052 - Common Stock - Currency: USD

0.0292  -0.02 (-38.91%)

After market: 0.0287 0 (-1.71%)

Buy % Consensus

77

ChartMill assigns a Buy % Consensus number of 77% to PEAR. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 5.44. This target is 18530.02% above the current price.
PEAR was analyzed by 12 analysts. The buy percentage consensus is at 77. So analysts seem to be have mildly positive about PEAR.
In the previous month the buy percentage consensus was at a similar level.
PEAR was analyzed by 12 analysts, which is quite many. So the average rating should be quite meaningful.

Related screens

PEAR Historical Analyst RatingsPEAR Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -15 -14 -13 -12 -11 -10 -9 -8 -7 -6 -5 -4 -3 -2 -1 0 2 4 6 8 10

Price Target & Forecast

Price Low Median Mean High 0.032.025.105.449.45 - 6,817.81% 17,365.75% 18,530.02% 32,263.01%

Related screens

PEAR Current Analyst RatingPEAR Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 1 2 3 4
Up and Down Grades
Date Firm Action Rating
2023-03-20 TD Cowen Downgrade Outperform -> Market Perform
2023-03-20 Chardan Capital Downgrade Buy -> Neutral
2023-03-20 Credit Suisse Downgrade Outperform -> Neutral
2022-11-16 Citigroup Maintains Buy
2022-11-15 Chardan Capital Maintains Buy
2022-11-15 Credit Suisse Maintains Outperform
2022-08-12 Chardan Capital Maintains Buy
2022-08-12 BTIG Maintains Buy
2022-07-26 Credit Suisse Maintains Outperform
2022-06-24 BTIG Maintains Buy
2022-05-17 Chardan Capital Maintains Buy
2022-05-17 Citigroup Maintains Buy
2022-01-26 B of A Securities Initiate Neutral
2022-01-20 Credit Suisse Initiate Outperform
2022-01-03 BTIG Initiate Buy
2021-12-22 Chardan Capital Initiate Buy
2021-12-16 Cowen & Co. Initiate Outperform